← Leaderboards
Justin Kawika Ichida
Harvard University
$14,163,279
Attributed
$18,357,417
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.1M · FY2011–25$10M$7.5M$5M$2.5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,357,417 · 6
By mechanism
R01$13,462,399 · 3
RF1$3,981,640 · 1
R00$736,537 · 1
K99$176,841 · 1
Top collaborators
- Neil Segil6 shared
- Hani Goodarzi4 shared
- Andrew P Mcmahon2 shared
Most similar at Harvard University
Same institution · by research overlap
- Victor Ovchinnikov$155,166
- Kevin Kit Parker$17,803,396
- Gregorio Valdez$5,120,222
Others in their field
Top investigators on “Neurons”
- Hongkui Zeng · Allen Institute$106,358,289
- Eric Martin McDade · Washington University$94,632,845
- Ed Lein · Allen Institute$90,858,363
- Randall J Bateman · Washington University$65,841,935
- John Morris · Washington University$65,018,684
- Paul S. Aisen · Cognition Therapeutics, Inc.$58,570,460
Research focus
NeuronsIn VivoMediatingAmyotrophic Lateral SclerosisMotor NeuronsDisease ModelGeneticNeurodegenerative DisordersNerve DegenerationIn VitroPhenotypePathway InteractionsTherapeutic TargetCellsAlzheimer&AposMutationGenesPreventProteinsInduced Pluripotent Stem CellDipeptidesC9orf72TechnologyTrafficking
Grant awards (29)
Leveraging Natural Phenotypic Variations of Heterogenous ALS Populations-in-a-Dish to Enable Scalable Drug Discovery$1,968,019
R01 · FY2025 · NS · contact PI
Leveraging natural phenotypic variations of heterogenous ALS populations-in-a-dish to enable scalable drug discovery$986,054
R01 · FY2024 · NS · contact PI
Validating Secretory Autophagy as a Therapeutic Strategy for Diverse Forms of ALS and FTD$686,752
R01 · FY2024 · NS · contact PI
Leveraging natural phenotypic variations of heterogenous ALS populations-in-a-dish to enable scalable drug discovery$987,822
R01 · FY2023 · NS · contact PI
Validating Secretory Autophagy as a Therapeutic Strategy for Diverse Forms of ALS and FTD$686,752
R01 · FY2023 · NS · contact PI
Leveraging natural phenotypic variations of heterogenous ALS populations-in-a-dish to enable scalable drug discovery$1,007,803
R01 · FY2022 · NS · contact PI
Validating Secretory Autophagy as a Therapeutic Strategy for Diverse Forms of ALS and FTD$620,824
R01 · FY2022 · NS · contact PI
Validating Secretory Autophagy as a Therapeutic Strategy for Diverse Forms of ALS and FTD$623,222
R01 · FY2021 · NS · contact PI
Diversity Supplement for Validating Secretory Autophagy as a Therapeutic Strategy for Diverse Forms of ALS and FTD (Santana)$79,217
R01 · FY2021 · NS · contact PI
Diversity Supplement for Validating Secretory Autophagy as a Therapeutic Strategy for Diverse Forms of ALS and FTD (Butler)$18,069
R01 · FY2021 · NS · contact PI
Validating Secretory Autophagy as a Therapeutic Strategy for Diverse Forms of ALS and FTD$674,414
R01 · FY2020 · NS · contact PI
Lineage reprogramming for hearing loss: development of drug screening and gene therapy approaches$583,311
R01 · FY2020 · DC
The role of pericytes in the aging brain and pathogenesis and treatment of neurodegeneration, and Alzheimer's A-beta and tau pathology$3,981,640
RF1 · FY2019 · AG · contact PI
Lineage reprogramming for hearing loss: development of drug screening and gene therapy approaches$648,339
R01 · FY2019 · DC
The Role of C9ORF72 Protein Function in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia$431,727
R01 · FY2019 · NS · contact PI
The Role of C9ORF72 Protein Function in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia$596,470
R01 · FY2018 · NS · contact PI
Lineage reprogramming for hearing loss: development of drug screening and gene therapy approaches$580,483
R01 · FY2018 · DC
Lineage reprogramming for hearing loss: development of drug screening and gene therapy approaches$65,028
R01 · FY2018 · DC
The Role of C9ORF72 Protein Function in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia$596,470
R01 · FY2017 · NS · contact PI
Lineage reprogramming for hearing loss: development of drug screening and gene therapy approaches$580,483
R01 · FY2017 · DC
The Role of C9ORF72 Protein Function in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia$45,347
R01 · FY2017 · NS · contact PI
The Role of C9ORF72 Protein Function in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia$12,908
R01 · FY2017 · NS · contact PI
Lineage reprogramming for hearing loss: development of drug screening and gene therapy approaches$570,385
R01 · FY2016 · DC
The Role of C9ORF72 Protein Function in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia$412,500
R01 · FY2016 · NS · contact PI
Conversion of Fibroblasts to fxnal Spinal Motor Neurons Using Defined Factor$243,644
R00 · FY2015 · NS · contact PI
Conversion of Fibroblasts to fxnal Spinal Motor Neurons Using Defined Factor$243,893
R00 · FY2014 · NS · contact PI
Conversion of Fibroblasts to fxnal Spinal Motor Neurons Using Defined Factor$249,000
R00 · FY2013 · NS · contact PI
Conversion of fibroblasts to functional spinal motor neurons using defined factor$87,633
K99 · FY2012 · NS · contact PI
Conversion of fibroblasts to functional spinal motor neurons using defined factor$89,208
K99 · FY2011 · NS · contact PI